Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA.
Department of Imaging Physics, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Cardiovasc Intervent Radiol. 2023 Mar;46(3):327-336. doi: 10.1007/s00270-022-03333-6. Epub 2023 Jan 6.
The aim of this study was to analyze the impact of using intra-procedural pre-ablation contrast-enhanced CT prior to percutaneous thermal ablation (pre-ablation CECT) of colorectal liver metastases (CLM) on local outcomes.
This retrospective analysis of a prospectively collected liver ablation registry included 144 consecutive patients (median age 57 years IQR [49, 65], 60% men) who underwent 173 CT-guided ablation sessions for 250 CLM between October 2015 and March 2020. In addition to oncologic outcomes, technical success was retrospectively evaluated using a biomechanical deformable image registration software for 3D-minimal ablative margin (3D-MAM) quantification. Bayesian regression was used to estimate effects of pre-ablation CECT on residual unablated tumor, 3D-MAM, and local tumor progression-free survival (LTPFS).
Pre-ablation CECT was acquired in 71/173 (41%) sessions. Residual unablated tumor was present in one (0.9%) versus nine tumors (6.6%) ablated with versus without using pre-ablation CECT, respectively (p = 0.024). Pre-ablation CECT use decreased the odds of residual disease on first follow-up by 78% (CI [5, 86]) and incomplete ablation (3D-MAM ≤ 0 mm) by 58% (CI [13, 122]). The odds ratio for residual unablated tumor for larger CLM was lower when pre-ablation CECT was used (odds ratio 1.0 with pre-ablation CECT vs. 2.52 without). Pre-ablation CECT use was not associated with improvements on LTPFS.
Pre-ablation CECT is associated with improved immediate outcomes by significantly reducing the incidence of residual unablated tumor and by mitigating the risk of incomplete ablation for larger CLM. We recommend performing baseline intra-procedural pre-ablation CECT as a standard imaging protocol.
Level 3 (retrospective cohort study).
本研究旨在分析经皮热消融(消融前 CT)前使用术中对比增强 CT(消融前 CECT)对结直肠肝转移(CLM)局部疗效的影响。
本研究回顾性分析了 2015 年 10 月至 2020 年 3 月期间,连续 144 例患者(中位年龄 57 岁[49,65]岁,60%为男性)的前瞻性肝脏消融登记资料,共进行了 173 次 CT 引导下消融治疗 250 个 CLM。除了肿瘤学结果外,还使用生物力学可变形图像配准软件对技术成功率进行了回顾性评估,用于 3D-最小消融边界(3D-MAM)的量化。采用贝叶斯回归估计消融前 CECT 对残留未消融肿瘤、3D-MAM 和局部肿瘤无进展生存期(LTPFS)的影响。
在 173 次消融治疗中,71 次(41%)采用了消融前 CECT。与未使用消融前 CECT 的患者相比,使用消融前 CECT 的患者中仅有 1 个(0.9%)肿瘤存在残留未消融肿瘤,而有 9 个(6.6%)肿瘤存在残留未消融肿瘤(p=0.024)。消融前 CECT 的使用使初次随访时残留疾病的可能性降低了 78%(95%CI [5,86]),使不完全消融(3D-MAM≤0mm)的可能性降低了 58%(95%CI [13,122])。对于较大的 CLM,使用消融前 CECT 时残留未消融肿瘤的比值比更低(使用消融前 CECT 的比值比为 1.0,未使用的比值比为 2.52)。消融前 CECT 的使用与 LTPFS 无改善相关。
消融前 CECT 通过显著降低残留未消融肿瘤的发生率和减轻较大 CLM 不完全消融的风险,显著改善了即刻疗效。我们建议将基线术中对比增强 CT 作为标准成像方案。
3 级(回顾性队列研究)。